TrialJournal of gastroenterology2010

Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.

Yuki Kimura et al.PubMed ↗Publisher ↗

No numbers read from the abstract.